Tarsus Pharmaceuticals is developing a groundbreaking pill to protect humans from Lyme disease, by killing ticks within 24 hours of ingestion and lasting up to 30 days. The drug, lotilaner, has been effective in a Phase II trial, killing up to 97% of ticks within a day. It could also potentially protect against other tick-borne diseases. This novel prevention method could be a game-changer in combating Lyme disease, which currently affects around 476,000 Americans yearly. Despite some skepticism about efficacy, the potential of this pill as a pre-exposure prophylaxis is promising and could significantly reduce the burden of tick-borne illnesses.
https://arstechnica.com/science/2024/03/tick-killing-pill-shows-promising-results-in-human-trial/